Cost-effectiveness of multi-gene panel sequencing (MGPS) for advanced non-small cell lung cancer (aNSCLC) patients.

6513Background: MGPS, compared to single-marker genetic testing (SMGT), has the potential to identify more patients who could benefit from targeted therapies, but the impact on outcomes and total c...